Sign In
Buy BCDA
$0.87
-0.0256 (-2.84%)
At Close: Jun 03, 2026
SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright
BioCardia to Participate in Upcoming Investor Conferences
08:00am, Friday, 13'th Aug 2021
SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease
BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
08:00am, Thursday, 12'th Aug 2021
SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
Will BioCardia, Inc. (BCDA) Report Negative Q2 Earnings? What You Should Know
04:44pm, Thursday, 05'th Aug 2021
BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies
08:00am, Thursday, 15'th Jul 2021
SAN CARLOS, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary
Why I've Taken A Small Position In BioCardia
01:00pm, Monday, 14'th Jun 2021
BCDA has candidate therapies that could potentially be curative of very prevalent heart diseases. The therapies have advanced to Phase 3 trials.
BioCardia, Inc. (BCDA) Reports Q1 Loss, Tops Revenue Estimates
12:55pm, Thursday, 13'th May 2021
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 14.29% and 31.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q4 Loss, Misses Revenue Estimates
09:52am, Tuesday, 30'th Mar 2021
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 48.39% and -58.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BioCardia Is Super Cheap With Multiple Shots On Goal
01:57pm, Thursday, 25'th Mar 2021
BioCardia has a leading-edge cardiac cell therapy platform. The company recently announced a settlement Term Sheet with Boston Scientific, BSX.
BioCardia Announces Clinical Leadership Changes
08:30am, Wednesday, 17'th Feb 2021
SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announ
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
01:54pm, Friday, 05'th Feb 2021
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
BioCardia Update on Cell Therapy Product Development and 2021 Milestones
08:30am, Tuesday, 02'nd Feb 2021
SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provide
Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia's Board of Directors
08:30am, Monday, 11'th Jan 2021
SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcomes Kri
Why These Health Care Stocks Are Moving Today
02:03pm, Wednesday, 30'th Dec 2020
Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimm
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies
08:30am, Wednesday, 30'th Dec 2020
Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and St
